Mediar Therapeutics signs collaboration, option deal with Ono Pharma on fibro-inflammatory disease antibodies

PUBT · 1d ago
Mediar Therapeutics signs collaboration, option deal with Ono Pharma on fibro-inflammatory disease antibodies
  • Sofinnova Partners portfolio company Mediar Therapeutics signed a collaboration and option deal with Ono Pharmaceutical on antibody programs for fibro-inflammatory diseases.
  • Ono secured an exclusive option for worldwide rights to develop and commercialize the programs; terms include an upfront payment and R&D funding.
  • Mediar will continue advancing MTX-474 (Phase 2 systemic sclerosis), MTX-463 (Phase 2 idiopathic pulmonary fibrosis; with Eli Lilly), MTX-439 (Phase 1 CKD fibrosis).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sofinnova Partners SAS published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.